MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...

The company said its EscharEx treatment had previously demonstrated its ability to effectively and rapidly remove damaged or ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure ...

said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers. The company said its EscharEx treatment had previously demonstrated its ability to effectively and ...

About Venous Leg Ulcers 1 EscharEx ® is a bioactive, multimodal debridement therapy for the treatment of chronic and other hard-to-heal wounds, currently in the advanced stages of clinical development ...

One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life (QoL) indicators.

Tactile Systems Technology (NASDAQ:TCMD – Get Free Report) is projected to release its earnings data after the market closes on Tuesday, February 18th. Analysts expect Tactile Systems Technology to ...

MediWound (NASDAQ:MDWD) stock climbed 4% following news that the company has initiated a Phase 3 study of its wound care product EscharEX in the treatment of venous leg ulcers, or VLU. The company ...

Lucknow: Varicose veins can lead to severe pain and complications if left untreated, said experts during a continuing medical ...

Sickle cell anaemia is a genetic blood disorder characterised by the production of an abnormal haemoglobin, known as haemoglobin S.